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Abstract
Preeclampsia is a hypertensive disease of pregnant women that is known to cause
detrimental physiological complications to both the mother and fetus. The hypertension
hypothesized to result from endothelial dysfunction may be improved therapeutically by
increasing Vascular Endothelial Growth Factor ligand concentration and it’s Vascular
Endothelial Growth Factor Receptor 2 (VEGF and VEGFR2). Together, this receptor
pathway may help overall vasodilation of key blood vessels linking the mother and fetal
placental unit, allowing for increased clinical pathologies of both. Previous studies have
also linked increased reactive oxygen species (ROS) production in preeclamptic
pregnancies to the damaged endothelial tissues of the placenta. This specific investigation
will use RUPP model to measure the effect of increased VEGF and VEGFR2 expression
on ROS production in placental tissues, measured using lucigenin-enhanced
chemiluminescence (LECL). These results may help further characterize ROS role in
hypertensive pregnancies physiological demise, and help indicate whether VEGFR may
serve as a potential therapeutic in treating preeclampsia.

Introduction
The hypertensive disease of pregnancy known as preeclampsia is responsible for
morbidity, perinatal death and preterm deliveries worldwide (Uzan et. al, 2011). The
clinical signature of preeclampsia includes edema, renal dysfunction, and fetal growth
restriction (Facemire, 2009). It has been hypothesized that the observed hypertension
results ultimately from endothelial cell dysfunction. This dysfunction induces damaging
vascular changes such as decreased vasodilation, increased vasoconstriction and
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vasospasms (Crews et. al, 2000). Decreased blood flow to the fetal placental unit arises
from the renal and cardiovascular changes known to be associated with the disease.
Vascular dysfunction and nutrient deficiencies often occur from the positive feedback
loop (Maynard, 2008). Oxidative stress may also arise as a result of any of the observed
defects.
VEGF and VEGFR2 are thought to play a significant role in vascular
homeostasis. As a vasodilator, the ligand VEGF binds VEGFR2 and potentially activates
endothelial nitric oxide synthase (NOS) (Crews et. al, 2000). Together, the two perform
significant roles in uterine remodeling, vasodilation and placental development
(Facemire, 2009).
In this study, the surgical Reduced Uterine Perfusion Pressure (RUPP) pregnant
rat model is used because of its similarities in utero-placental under-perfusion of
preeclampsia in humans. The RUPP model has replicated the maternal hypertension,
vascular dysfunction and fetal demise commonly observed in the preeclamptic pathology
of humans in a previous investigation (Reho et. al, 2011). After two weeks of gestation, a
surgical procedure is performed to diminish uterine blood flow approximately 40%.
Specifically, small clips are clamped around the abdominal aorta and the uterine-ovarian
arteries (Crews et. al, 2000). This decreased blood flow causes the decreased uterine
perfusion, and therefore deprives the fetus of a sufficient blood volume. This cascade
adds to the maternal hypertension, as the mother’s physiology must then work harder to
provide the fetal-placenta with sufficient blood, oxygen and nutrients (Crews et. al,
2000).
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Oxidative stress has previously been investigated for
its role in the pathophysiology of preeclampsia. Production
of free radicals could impact pregnancy by altering the
normal growth and function of the placental unit (Burton,
2009). Free oxygen radicals have the potential to oxidize
fatty acids in lipids and amino acids in proteins, damaging
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cells and causing overall organ dysfunction (Sies, 1985).
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physiology because of the ROS damage to the endothelium
of placenta (Draganovic, 2016).
Dr. Ramirez’s lab has demonstrated that vasoconstriction occurred as a result of
increased oxidative stress in RUPP models while investigating the effects of ascorbic
acid, a compound with antioxidant properties (Ramirez et. al, 2011). The aim of the
overall project is to examine whether overexpression of VEGFR2 improves the uteroplacental blood flow and the maternal and fetal clinical pathologies. The experimental
schematic can be seen in Figure 2. Placental tissues have been suggested in a previous
study to contribute to the overproduction VEGFR; therefore contributing to the overall
excessive vascular permeability observed in preeclamptic physiology (Grummer, 2009).
Decreased perfusion via altered vascular reactivity may confer placental oxidative stress
in the RUPP model. The specific aim of this branch of the investigation is analyzing ROS
production in RUPP model placentas with and without increased VEGFR2 expression.
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↑ VEGFR2
⇓
↑ NO
⇓
↑ Vascular Relaxation
⇓
↑ Placental Perfusion
⇙
⇘
Maternal:
↓Maternal hypertension
Restore phenotype small arteries
↑Uterine artery blood flow
↓ Oxidative stress

Fetal:
↑Placental insufficiency
Reverse growth restriction
↓Fetal morbidity

Figure 2: The approach to investigate the mechanism of VEGF signaling by selectively overexpressing
VEGFR2 in the treated RUPP model.

ROS production will be used as an indicator of overall pathology. A decrease may
be linked to clinical improvement or impairment of the receptor expression. To measure
the levels of oxidative stress in the rat’s placental tissues, a luminometer will be used.
This tool will measure the emission of light from the chemical reaction between lucigenin
(bis-N-methylacridinium nitrate) and superoxides present in the placental homogenate.
LECL serves as one of the most convenient and sensitive approaches for ROS detection
(Yamazaki, 2011). Using this method, superoxides can be quantitatively monitored by the
luminometer by collecting reactive light units (RLU) produced by the reaction of
superoxide with lucigenin (Yamazaki, 2011). A detailed depiction of the chemical
reaction of lucigenin with a superoxide is seen in Figure 3.
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Figure 3: Hypothesized reactions undergone in luminometer between lucigenin and a superoxide in order
to generate chemiluminescence (Lu, 2006). NMA* = NMA + photon. Created using ChemDraw
Professional, Version 16.0, PerkinElmer Informatics.
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Upon interaction with the superoxide, the lucigenin will undergo a single electron
reduction, forming a cation radical. The radical quickly binds to the superoxide, yielding
lucigenin dioxetane as a brief intermediate. Lucigenin dioxetane undergoes an internal
rearrangement, creating a N-methylacridone (NMA) molecule, and a NMA radical ion
(NMA*) (Lu, 2006). Chemiluminescence occurs as a result of NMA* relaxing from its
excited state, returning to the ground state where it emits light at 470 nm. This relaxation
is then detected and interpreted by the luminometer as RLU’s (Vásquez-Vivar, 1997).
A baseline with no homogenate sample will be run for control, and a superoxide
baseline with lucigenin and a homogenate sample is run for comparison to the treated
groups, treated with NADPH oxidase and tiron respectively.
NADPH oxidase is a flavoprotein that enzymatically facilitates the single electron
reduction of oxygen while using NADPH is oxidized to complete the redox reaction. The
end product is a superoxide anion. The NADPH oxidase
has previously been suggested as a major source of cellular
superoxides in rabbit vascular tissues (Vásquez-Vivar,
1997). Therefore, we would expect the NADPH treated
sample to cause a spike in superoxides, and therefore

Figure 4: Chemical structure of

increased RLU’s collected by the luminometer. Tiron, who’s

Tiron, a superoxide radical

chemical structure can be seen in Figure 4, has a radical

scavenger. Created using

scavenging mechanism that is hypothesized to occur by ROS

ChemDraw Professional,

via direct oxidation (Taiwo, 2008). Upon oxidation, the

Version 16.0, PerkinElmer
Informatics.

reduced Tiron molecule will create a hydroquinone.
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Therefore, we expect a decrease in lucigenin chemiluminescence in the Tiron-treated
sample (Münzel, 1995). Three different experimental groups were proposed to be
analyzed using luminometer technology- SHAM, RUPP and RUPP treated with the
nanoparticles. We hypothesize that overexpression of VEGFR2 will increase blood flow
in the maternal-placental unit, and thus lower oxidative stress. If this holds true, then we
should see decreased oxidative stress signals in our data collected from the treated RUPP
model (Grummer, 2009).

Materials and Methods
Animal Maintenance
All animal studies were approved by IACUC at the University of Akron .The rats
used in the investigation were handled and housed in the vivarium of the University of
Akron. Two lab technicians and one trained medical veterinarian handled the animals on
a daily basis. The animals were observed for illness and any adverse effects from
experimental treatments. Records of their health were logged twice a week. Medical
documentation was updated and available on each of the rat’s cage card when in the lab.
Standard Operating Procedures from the IACUC were followed in all aspects.

Buffer Preparation
1 L of 10X HEPES buffer was first prepared using 83 g of NaCl, 3.50 g of KCl,
1.60 g of KH2PO4, 2.88 g of MgSO4*7H2O, 3.68 g of CaCl2*2H2O, and 23.83 g of
HEPES. The buffer was brought to pH 7.37 by using 1 M NaOH. 10X HEPES was then
diluted with DI water tenfold to make 1X HEPES followed by the addition of 0.5 g of
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glucose and the pH was checked again. Before incorporation into lucigenin assay
samples, 1X HEPES was heated for ten minutes at 37 C, re-evaluated and the pH was
adjusted to 7.37 again to ensure it as optimal physiological comparison. The pH was
measured over the course of experiments to ensure it remained stable. 10X HEPES was
stored for several weeks, however 1X HEPES was freshly prepared before each use.

Preparation of protein samples
Placental tissues were isolated from frozen rat placenta collected six-ten months
prior to experimentation. Each sample was homogenized prior to the measurement of
protein concentration by Bradford Assay. The preparation entailed collecting ~0.3 g
tissue and adding 1X HEPES buffer (pH ~7.37) at 0.1 g/mL. An example can be seen in
Sample Calculation 1.

𝑡𝑖𝑠𝑠𝑢𝑒 𝑤𝑒𝑖𝑔ℎ𝑡 = 0.327 𝑔
0.327 𝑔
= 3.27 𝑚𝐿
0.1
3.27 𝑚𝐿 − 0.327 𝑚𝐿 = 2.943 𝑚𝐿 1𝑋 𝐻𝐸𝑃𝐸𝑆 𝑏𝑢𝑓𝑓𝑒𝑟 𝑛𝑒𝑒𝑑𝑒𝑑
Sample Calculation 1: Above is an example of the equations used to find the appropriate buffer volume
needed to make the homogenate.

The protein solution was kept on ice for the remainder of preparation.
Approximately 50 μL of protease inhibitor (100x) was added before homogenizing until
smooth liquid was observed. Homogenate was then spun in an IEC Centra CL2
centrifuge at 3000 RPM for six-eight minutes. The protein supernatant was collected and
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the cell pellet was disposed. Protein was stored at -80 C until assayed. SHAM placenta
was used to create the first set of data. RUPP placenta without treatment of VEGF was to
be used the second time, while RUPP placenta treated with VEGF was to be used for the
final data set.

Measurement of Protein Concentration in Placental Homogenate Samples
A standard Bradford assay purchased from Sigma was run each day tissues were
assayed to generate a standard curve. This curve was used to find the protein
concentration in each of the homogenate samples analyzed based on their recorded
absorbance. The amount of protein present in each sample is relative to the amount of
RLU’s measured using the lucigenin assay. Six standard samples were prepared, with a
total volume of 3000 μL, and measured in a Spectrometer at 595 nm.
The first sample contained (0 μL BSA + 2400 μL DI water + 600 μL Bradford
Reagent). The second sample contained (3.9 μL BSA + 2397 μL DI water + 600 μL
Bradford Reagent). The third sample contained (7.5 μL BSA + 2391μL DI water + 600
μL Bradford Reagent). The fourth sample contained (15 μL BSA + 2385 μL DI water +
600 μL Bradford Reagent). The fifth sample contained (22.5 μL BSA + 2376 μL DI
water + 600 μL Bradford Reagent). The sixth sample contained (30 μL BSA + 2370 μL
DI water + 600 μL Bradford Reagent). Four placental samples were prepared with (200
μL HMG + 1800 μL DI + 600 μL Bradford) and measured as well. Their measurements
can be seen in Table 1. The absorbance measurements from four representative protein
samples were averaged and plotted on the standard curve, seen in Figure 5. R2 values
were obtained to ensure standards accuracy.
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Measurement of ROS Production
The lucigenin assay was used to measure chemiluminesence exhibited by
superoxides formed via NADPH oxidase, and to confirm specificity by the ROS
scavenger, Tiron. The protocol for the Turner Biosystems luminometer called for the use
of lucigenin at 100 μmol/L. Once properly diluted, the lucigenin stock was covered in foil
when being stored in the freezer, and was carefully added to samples in a dark room to
prevent interaction with light waves. Once in the samples, each bullet tube that contained
lucigenin was covered in foil in order to prevent potential light wave interaction. Before
use, the pH of 1X HEPES buffer was adjusted to 7.37, incubated at 37 C for ten minutes,
then re-examined to ensure proper pH prior to the beginning of the analysis. A baseline
sample was prepared with (400 μL 1X HEPES buffer + 0.6 μL lucigenin) before being
placed in luminometer. Fifteen RLU collections were taken. Ideally, this should reflect
the lowest value because no homogenate or protein was present in the sample.
A superoxide baseline sample was prepared with (100 μL HMG + 400 μL 1X
HEPES buffer + 0.6 μL lucigenin). The sample was incubated in the water bath for three
minutes at 37 C. A stimulated superoxide sample was prepared using 10mM NADPH
(100 μL HMG + 400 μL 1X HEPES buffer + 0.6 μL lucigenin + 10 μL of 10 mM
NADPH), and incubated in a water bath at 37 C for three minutes. The addition of
NADPH was to produce ROS in an NADPH oxidase-dependent manor, causing a spike
in the signal detected in this sample. After preparation, the bullet tube was placed in the
luminometer and fifteen RLU collections were taken.
A final sample was prepared with 100 μM/L Tiron (100 μL HMG + 400 μL 1X
HEPES buffer + 0.6μL lucigenin + 50 μL Tiron) and incubated in a water bath at 37 C
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for three minutes. After incubation, the bullet tube was placed in the luminometer and
fifteen RLU’s were collected.
The parameters of the luminometer were preset to the lucigenin protocol. Reactive
light unit (RLU) measurements for each sample were taken constantly every five seconds
until fifteen measurements were recorded.

Statistics
In order to normalize the data, the RLU’s were to be divided by the concentration
of protein found in the homogenate sample used during that particular trial. This data
could then be used in a T-test and ANOVA to compare ROS measurements between
experimental groups.

Results and Discussion
In order to standardize our luminometer measurements, we first normalized our
protein concentrations for each of our placental samples. The measurements can be seen
in Table 1.
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Table 1: Absorbance values for standards used in the Bradford assay.

Absorbance’s Collected to Generate Standard Curve
μL in Assay
μg in assay Abs (595nm)
Standard Samples
3000

0

0

3000

390

0.046

3000

750

0.09

3000

1500

0.148

3000

2250

0.217

3000

3000

0.261

Unknown Samples
2600

61.44

0.566

2600

56.78

0.524

2600

61.00

0.562

2600

61.33

0.565

Average protein concentration

60.14
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Abs (595 nm)

0.3

Standard Curve

0.25
0.2

y = 9E-05x + 0.013
R² = 0.9889

0.15
0.1
0.05
0
0

1000

2000
3000
ug Protein in Assay

4000

Figure 5: Standard curve developed using six standards and the Bradford Assay protocol. Absorbances
were recorded at 595 nm, and the linear fit equation generated was used to find the protein concentrations
of the four homogenate tissue samples. The R2 value indicates a relatively linear fit, making it a suitable
equation to find protein concentrations of unknown samples.

The standard curve was corrected with an absorbance reading of 0 for a protein
concentration of 0. The linear fit equation 𝑦 = 9 ∗ 10−5 𝑥 + 0.013 (y = mx + b) was used
to find the unknown samples protein concentrations. The absorbances at 595 nm were
plugged in for y, and solved for x in order to find protein concentration in the sample.
The corresponding arithmetic can be seen in Sample Calculation 2. Four homogenate
samples were made so their protein concentrations could be averaged, yielding an
average protein concentration of 60.14 μg/μL.
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𝑦 = 9 ∗ 10−5 𝑥 + 0.013
0.566 = 9 ∗ 10−5 𝑥 + 0.013
𝑥 = 6144.44 𝑢𝑔/𝑚𝐿
6144.44 𝓊𝑔
61444.4 𝓊𝑔
∗ 10 =
= 61.44 𝓊𝑔/𝓊𝐿
𝑚𝐿
𝑚𝐿
Sample Calculation 2: Linear equation used to find protein concentrations of unknown placental tissues,
created by the standard curve seen in Figure 5. Because the homogenate samples were diluted 10 fold, this
had to be factored into the final protein calculation.

Once the protein concentrations were found, the homogenate samples were taken
to the luminometer to measure RLUs. Fifteen data points were collected for each of the
four experimental conditions, using two different protein samples. The normalized data is
shown in Figure 6.
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Signal Normalized (RLU/ug of
protein)

Normalized SHAM Luminometer Data
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Baseline

Superoxide
Baseline
Sample 1

NADPH

Tiron

Sample 2

Figure 6: Measurement of superoxide levels in placental tissue isolated from SHAM animals. Data was
normalized by dividing RLU signal strength by concentration of protein found within the sample. The
baseline was developed using a chemiluminesence assay and compared to a positive control (superoxide
baseline). The NADPH-treated samples were stimulated to produce ROS and spike RLU production, while
the Tiron-treated samples were meant to scavenge the superoxide anions, decreasing RLU signal.

At this point, only SHAM placental tissues were tested and not the VEGF
experimental groups. Each of the two samples tested in the luminometer were collected
from SHAM placental tissues. The fifteen replicate measurements for each condition
were averaged and later normalized by dividing them by the protein concentration found
in that particular sample. This allowed for the comparison of both SHAM samples,
despite their differences in protein concentration. The baseline sample was meant to act
as a control to compare to the superoxide baseline that contained the homogenate sample.
The baseline should have the lowest lucigenin stimulation because it contained no
homogenate, and therefore we would expect the superoxide baseline to have higher RLU
signal. Although the sample 1 superoxide baseline appeared to have a higher signal than
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the baseline, the error bars demonstrate there was no significant difference between the
superoxide baseline and lucigenin baseline. Both NADPH-stimulated samples showed an
increase in RLU production, as predicted. Similarly, the data reflect that the Tiron did act
as a superoxide scavenger, seeking out ROS and preventing the lucigenin from
interacting with the free electrons. This led to an overall decrease in RLU production in
comparison to the NADPH treated samples.

Conclusion
The detrimental capability of oxidative stress in hypertensive pregnancies has
been an important topic of study to medical professionals worldwide (Draganovic, 2016).
This investigation was meant to test the oxidative stress levels between three
experimental groups- SHAM, RUPP, and RUPP models with increased VEGFR2
expression. Both RUPP models represented preeclamptic pathology (Reho et al., 2011).
RUPP treated with LTP nanoparticles were hypothesized to increase VEGFR2
expression. The SHAM models were used as a control to compare ROS levels of normal
pregnant rats with those in a hypertensive state (Reho et al., 2011).
We would predict that the RUPP models would exhibit higher levels of oxidative
stress due to the decreased uterine perfusion, vasoconstriction and hypertensive
physiology when compared to the untreated SHAM models (Ramirez, 2015). Treatment
of LTP nanoparticles was meant to increase VEGFR2 expression. Decreased VEGFR2
expression is linked to preeclampsia pathology (Grummer, 2009). Treatment of rat’s
experimental preeclampsia is predicted to increase VEGF signaling and enhance the
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overall uterine perfusion. We would expect to see a decrease in oxidative stress when
analyzing these tissues samples (Grummer, 2009).
During the time of writing, the experiment was still continuing. Only data
collected from the SHAM group was recorded to this point, and some difficulties were
experienced in the process. Only two protein samples produced adequate RLU
measurements, because for all other samples the baselines did not generate accurate
measurements. Without proper baseline measurements, no valid comparisons could be
made to the experimental samples. Several obstacles prevented the collection of multiple
adequate data sets, including the failure to ensure proper pH before testing for ROS by
the luminometer. Improper pH may have denatured the protein samples before processing
in the luminometer. In an attempt to correct this problem, all homogenate samples and
buffers were re-made, ensuring proper pH every step of the way before testing the entire
experimental sample. Unfortunately, this did not seem to correct the inaccurate baseline
readings obtained. A new lucigenin sample was ordered and the stock was re-made to
correct any discrepancies that may have come from it, as it is a very light-sensitive
chemical and could have been another cause of the inaccurate baselines. Even with fresh
lucigenin reagent, RLU readings were still not as predicted. In addition, the Turner
Biosystems luminometer may have been responsible for inaccurate RLU measurements,
as it had not been calibrated since our use in the experiment.
Although there were two SHAM homogenate samples that aligned with what was
predicted to happen, there was not enough significant evidence to support our hypothesis
at this time. More SHAM samples should be analyzed, and the other experimental groups
should be tested as well to draw accurate conclusions from the total data. Further
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investigation the cross-talk between VEGF signaling and ROS production could help find
potential pharmaceuticals and therapeutics to combat preeclampsia, bettering the lives of
the mother and the fetus.
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Safety Appendix
Dr. Ramirez and his graduate students taught safety training. The use of Personal
Protective Equipment was used to minimize risk of injury while dealing with chemicals.
Lab gloves and safety glasses also reduced risk of incidence. Appropriate LUC-0-ING
protocol was followed when using the luminometer in reference to the Turner Biosystems
manual. Salts for making HEPES buffer were handled with care, and cautious handling of
the 1 M NaOH was used when pHing the buffer. pH waste was dumped in a specified
container and excess buffer was diluted and disposed of down the drain. No injuries or
major spills occurred in the laboratory.
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